4.0 Review

Treating morbid obesity in cirrhosis: A quest of holy grail

期刊

WORLD JOURNAL OF HEPATOLOGY
卷 7, 期 28, 页码 2819-2828

出版社

BAISHIDENG PUBLISHING GROUP INC
DOI: 10.4254/wjh.v7.i28.2819

关键词

Obesity; Intragastric balloon; Antiobesity drugs; Bariatric surgery; Cirrhosis

向作者/读者索取更多资源

The problem of obesity is increasing worldwide in epidemic proportions; the situation is similarly becoming more common in patients with cirrhosis which negatively affect the prognosis of disease and also makes liver transplantation difficult especially in the living donor liver transplantation setting where low graft to recipient weight ratio negatively affects survival. Treatment of obesity is difficult in cirrhosis due to difficulty in implementation of lifestyle measures, limited data on safety of anti-obesity drugs and high risk of surgery. Currently approved anti-obesity drugs have limited data in patients with cirrhosis. Bariatric surgery remains an option in selected compensated cirrhotic patients. Endoscopic interventions for obesity are emerging and are quite promising in patients with cirrhosis as these are minimally invasive. In present review, we briefly discuss various modalities of weight reduction in obese patients and their applicability in patients with cirrhosis.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.0
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据